Comparison Of Long-Term Outcomes And Refractive Stability Following Smile Versus Smile Combined With Accelerated Cross Linking (Smile Xtra)

Published 2022 - 40th Congress of the ESCRS

Reference: FPT07.07 | Type: Free paper | DOI: 10.82333/sqq1-5r71

Authors: Hemanth Reddy Vanga* ¹ , Sri Ganesh ¹ , Sheetal Brar ¹

¹NETHRADHAMA SUPERSPECIALITY EYE HOSPITAL, BENGALURU,BENGALURU,India

Purpose

To compare the long-term safety, efficacy, predictability and refractive stability following SMILE versus SMILE combined with accelerated cross linking (SMILE XTRA)

Setting

Nethradhama Super Speciality Eye Hospital, Bangalore, India

Methods

This retrospective study included 54 eyes of SMILE and 52 eyes of SMILE XTRA treated for normal and borderline cases of myopia/ myopic astigmatism respectively, based upon certain pre-defined topographic features and risk factors. Patients in both the groups were matched for age and refractive error. The mean post-operative follow-up was 22.18± 10.41 months.

Results

At the end of follow-up, the mean sphere, cylinder and SE reduced to -0.03, -0.09 and -0.08D in SMILE and -0.06, -0.15, and -0.13D in the SMILE XTRA group, p=0.17. Ninety-three % and 92% eyes remained within ±0.50D with 94 % and 88% eyes maintained a UDVA of 20/20 or better in SMILE and SMILE Xtra groups respectively. Safety and Efficacy indices for SMILE group were 1.16 and 1.03 and for the SMILE Xtra group were 1.06 and 0.93. No eye in either group had post-operative ectasia or enhancement done for significant residual refractive error.

Conclusions

Both SMILE and SMILE XTRA resulted in similar amount of regression. Contrary to the belief, SMILE combined with accelerated cross linking did not result in a hyperopic outcome over a long- term follow up, when used to treat borderline cases.

Financial disclosure of all authors: Dr. Sri Ganesh and Dr. Sheetal Brar are consultants for Carl Zeiss Meditec